NuVasive Investor Relations

NuVasive is a world leader in minimally invasive, procedurally integrated spine solutions. From complex spinal deformity to degenerative spinal conditions, NuVasive is transforming spine surgery with innovative technologies designed to deliver reproducible and clinically proven surgical outcomes.

Press Release

NuVasive to Participate as Double Diamond Sponsor at Scoliosis Research Society Annual Meeting

SAN DIEGO, Sept. 12, 2022 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced it will continue its partnership with the Scoliosis Research Society (SRS) as a double diamond sponsor and will attend the 57th Annual Meeting held September 14-17, 2022 in Stockholm, Sweden. 

"SRS is a leading society in our industry, and we share a common vision to support research and education efforts to advance care for all patients with spinal deformities," said Chris Barry, chief executive officer at NuVasive. "It is clear that procedures integrated with enabling technology are critical in larger, complex deformity cases, and our partnership with SRS helps further our ability to push the standard of spine surgery toward more intelligent solutions."

As part of the SRS Annual Meeting, NuVasive will host a workshop titled "Over a decade of MAGEC®: outcomes and efficacy through data and real-world experiences" presented by Professor Kenneth Cheung, Professor Ralf D. Stücker, and Dr. Paul Sponseller, and moderated by Dr. Amer Samdani on September 15, 2022. This case-based discussion will cover the MAGEC system's impact on the panel's early-onset scoliosis patients and their practices over the last 10+ years. NuVasive's Senior Vice President of Scientific Affairs, Kyle Malone, will also share a brief scientific data update on the MAGEC system.

NuVasive has partnered with SRS, the premier international society aimed at fostering optimal care for all patients with spinal deformities, since 2007. The Company's ongoing double diamond sponsorship supports clinical workshops, hands-on educational courses, and fellowship and grants for more than 1,500 of the world's leading spine surgeons, researchers, physician assistants, and orthotists who are involved in the research and treatment of spinal deformities.

About NuVasive

NuVasive, Inc. (NASDAQ: NUVA) is the leader in spine technology innovation, with a mission to transform surgery, advance care, and change lives. The Company's less-invasive, procedurally integrated surgical solutions are designed to deliver reproducible and clinically proven outcomes. The Company's comprehensive procedural portfolio includes surgical access instruments, spinal implants, fixation systems, biologics, software for surgical planning, navigation and imaging solutions, magnetically adjustable implant systems for spine and orthopedics, and intraoperative neuromonitoring technology and service offerings. With more than $1 billion in net sales, NuVasive operates in more than 50 countries serving surgeons, hospitals, and patients. For more information, please visit

Forward-Looking Statements

NuVasive cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, risks associated with acceptance of the Company's surgical products and procedures by spine surgeons and hospitals, development and acceptance of new products or product enhancements, clinical and statistical verification of the benefits achieved via the use of NuVasive's products, the Company's ability to adequately manage inventory as it continues to release new products, its ability to recruit and retain management and key personnel, and the other risks and uncertainties described in NuVasive's news releases and periodic filings with the Securities and Exchange Commission. NuVasive's public filings with the Securities and Exchange Commission are available at NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made. 


Cision View original content to download multimedia:

SOURCE NuVasive, Inc.

Investor contact: Juliet C. Cunningham, NuVasive, Inc., 858-210-2129,; Media contact: Melanie Ordoñez, NuVasive, Inc., 858-722-3899,